https://www.weightlossrankings.org/research/mounjaro-vs-zepbound-tirzepatide-disambiguation Weight Loss Rankings en 2026-05-10T00:00:00.000Z Mounjaro vs Zepbound: Same Drug, Different Brands — Why the Distinction Matters for Coverage and Cost https://www.weightlossrankings.org/research/glp1-spironolactone-pcos-potassium-evidence Weight Loss Rankings en 2026-05-10T00:00:00.000Z Spironolactone with GLP-1: Potassium, PCOS, and Combined Use Evidence https://www.weightlossrankings.org/research/oregon-medicaid-ohp-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z Oregon Medicaid (Oregon Health Plan) GLP-1 Coverage 2026: Pattern #29 — HERC Prioritized List Guideline Note 5 Evidence-Based-Coverage Exclusion (Structurally Unique in 50-State Series) + Wegovy CV + Wegovy/Liraglutide MASH (August 2024 Early Adoption Before FDA Approval) + Zepbound OSA + Foundayo on PDL No PA Criteria + No Third-Party PBM + DURM/OSU Academic-Pharmacy Model + 15 CCOs https://www.weightlossrankings.org/research/connecticut-medicaid-husky-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z Connecticut Medicaid HUSKY Health GLP-1 Coverage 2026: Pattern #30 — Partial-Reversal Triple-Carve-Out State (PA 23-171 Statutory Mandate Never Operationalized for GLP-1s + Serial Termination Jan 15 → June 14 → Aug 1, 2025 + Wegovy MACE + Zepbound OSA + Wegovy MASH with HUSKY B Exclusion) + SPA 25-0014 Phentermine/Orlistat-Only + FFS-Only Since 2012 + Gainwell/Prime/Acentra Triple-Vendor PBM Structure https://www.weightlossrankings.org/research/nevada-medicaid-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z Nevada Medicaid GLP-1 Coverage 2026: Pattern #31 — Statutory-Mandate-Failed Categorical-Exclusion State with Sole Wegovy CV-Only Carve-Out (Most Restrictive in Series) — Statewide MCO Expansion + Single PDL January 1, 2026 — Nevada Health Authority Reorganization July 1, 2025 — SB 244 Died June 3, 2025 https://www.weightlossrankings.org/research/louisiana-medicaid-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z Louisiana Medicaid GLP-1 Coverage 2026: Pattern #28 — Expansion-State Dual-PDL-Listed Carve-Out (Wegovy CV-Only + Zepbound OSA-Only + Orlistat) + PATIENT TREATMENT AGREEMENT + ULM College of Pharmacy FFS PA + 5-PBM Post-Oct-2025 MCO Architecture + SB 433 Senate 31-0 Active Legislative Expansion (House Pending, Jan 1, 2027 Effective) https://www.weightlossrankings.org/research/glp1-creatine-lean-mass-preservation-evidence Weight Loss Rankings en 2026-05-10T00:00:00.000Z Creatine on GLP-1: Lean Mass Preservation, Hydration, and Combined Use Evidence https://www.weightlossrankings.org/research/glp1-hrt-menopause-estrogen-weight-loss-evidence Weight Loss Rankings en 2026-05-10T00:00:00.000Z HRT and GLP-1 Weight Loss: Estrogen, Progesterone, Menopause Timing, and Combined Use Evidence https://www.weightlossrankings.org/research/colorado-medicaid-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z Colorado Medicaid GLP-1 Coverage 2026: Pattern #27 — Dual-Carve-Out Regulatory-Exclusion State (Wegovy CV BMI ≥ 25 Most Permissive in Series + Wegovy MASH + Zepbound OSA) + SB 25-048 Large-Group Commercial Mandate With Explicit Medicaid/CHP+ Carve-Out + MedImpact PBM Transition April 1 2026 + University of Colorado DUR Board https://www.weightlossrankings.org/research/south-carolina-medicaid-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z South Carolina Medicaid GLP-1 Coverage 2026: Pattern #26 — Policy-Reversal Termination, 14-Month Coverage Window (Nov 2024–Dec 2025, SHORTEST in 50-State Series), Lowest-Documentation Elimination-Cluster Member, Healthy Blue Formulary Trap, Magellan/Prime Therapeutics sPDL + 5-MCO Architecture https://www.weightlossrankings.org/research/new-hampshire-medicaid-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z New Hampshire Medicaid GLP-1 Coverage 2026: Pattern #25 — Policy-Reversal Termination via Single DHHS Memo (October 9, 2025) + 4-Indication Carve-Out Without Published Thresholds + SB 455 Blocked 13–2 + KFF Four-State Elimination Cluster https://www.weightlossrankings.org/research/oklahoma-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Oklahoma Medicaid GLP-1 Coverage 2026: Pattern #24 — Triple-Carve-Out Regulatory-Exclusion State (Wegovy CV + MASH, Zepbound OSA, Imcivree Monogenic-Obesity) with OU College of Pharmacy-Administered PA https://www.weightlossrankings.org/research/iowa-medicaid-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z Iowa Medicaid GLP-1 Coverage 2026: Pattern #32 — Dual-Authority Regulatory Exclusion + Unified PA Form 470-0058 (Wegovy MACE + Zepbound OSA + Wegovy MASH) — PDL Comment Code 12 — Optum PBM https://www.weightlossrankings.org/research/new-mexico-medicaid-turquoise-care-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z New Mexico Medicaid (Turquoise Care) GLP-1 Coverage 2026: Pattern #33 — Regulatory-Exclusion State with Legacy-AOM Carve-In (6 Older AOMs with PA) + All Four Modern GLP-1s Explicitly Not Covered — NMAC 8.324.4.14(A)(8) — KFF YMYL Trap — HSD→HCA Consolidation July 1, 2024 — SB 193 (2025) Died — Prime Therapeutics PDL 2026 https://www.weightlossrankings.org/research/arkansas-medicaid-glp1-coverage-pa-pathway-2026 Weight Loss Rankings en 2026-05-10T00:00:00.000Z Arkansas Medicaid GLP-1 Coverage 2026: Pattern #34 — Three-Program-Bifurcated Regulatory Exclusion + 3 Separate DUR-Board PA Documents (Wegovy CV July 2024 · Zepbound OSA April 2025 · Wegovy MASH Oct 2025) + ACT 628 Legislative Ratification — Prime Therapeutics PBM https://www.weightlossrankings.org/research/tirzepatide-diarrhea-mechanism-management Weight Loss Rankings en 2026-05-10T00:00:00.000Z Why Does Tirzepatide Cause Diarrhea? (Onset, Mechanism, and Management) https://www.weightlossrankings.org/research/tirzepatide-headaches-mechanism-management Weight Loss Rankings en 2026-05-10T00:00:00.000Z Why Does Tirzepatide Cause Headaches? (Frequency, Mechanism, and When to Call Your Doctor) https://www.weightlossrankings.org/research/glp1-fatigue-mechanism-management Weight Loss Rankings en 2026-05-10T00:00:00.000Z Why Does Tirzepatide / Semaglutide Make You Tired? GLP-1 Fatigue: Onset, Mechanism, and Management https://www.weightlossrankings.org/research/glp1-plateau-compounded-not-working-decision-tree Weight Loss Rankings en 2026-05-10T00:00:00.000Z Why Am I Not Losing Weight on Compounded Tirzepatide / Semaglutide? (Plateau Decision Tree) https://www.weightlossrankings.org/research/peptides-for-weight-loss-evidence-review Weight Loss Rankings en 2026-05-10T00:00:00.000Z What Are Peptides for Weight Loss? Definition, Compounded Peptide Landscape + Evidence Review https://www.weightlossrankings.org/research/wellbutrin-xl-weight-loss-evidence Weight Loss Rankings en 2026-05-10T00:00:00.000Z Wellbutrin XL for Weight Loss: How Fast and How Much? (Evidence Review) https://www.weightlossrankings.org/research/alabama-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Alabama Medicaid GLP-1 Coverage (2026): Pattern #23 — PDL-Enumerated OSA-Only Zepbound Carve-Out + Off-PDL Cardiac-Criteria Wegovy MACE Exclusion — No Chronic-Weight-Management Coverage https://www.weightlossrankings.org/research/naltrexone-contrave-weight-loss-evidence Weight Loss Rankings en 2026-05-10T00:00:00.000Z Naltrexone for Weight Loss + How Contrave Actually Works: Evidence Review https://www.weightlossrankings.org/research/unitedhealthcare-glp1-prior-authorization-guide Weight Loss Rankings en 2026-05-10T00:00:00.000Z UnitedHealthcare GLP-1 Prior Authorization Guide: Wegovy, Zepbound, and Saxenda PA Criteria (2026) https://www.weightlossrankings.org/research/missouri-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Missouri Medicaid (MO HealthNet) GLP-1 Coverage (2026): Pattern #22 — Affirmative Coverage with Wegovy Demoted to MACE/MASH-Only + Foundayo Preferred First in 22-State Series + Dual Federal Model LOIs https://www.weightlossrankings.org/research/kentucky-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Kentucky Medicaid GLP-1 Coverage (2026): Pattern #21 — Nullified-Amendment Exclusion State (SB 65 Veto Override April 14, 2026) + Most Permissive MACE Pathway in Series (BMI ≥ 27) + T2D Exclusion From MACE/MASH/OSA Carve-Outs + KEHP-Medicaid Jurisdiction Inversion https://www.weightlossrankings.org/research/anthem-glp1-prior-authorization-guide Weight Loss Rankings en 2026-05-10T00:00:00.000Z Anthem GLP-1 Prior Authorization Guide: Verbatim PA Criteria for Wegovy, Zepbound, and Saxenda (2026) https://www.weightlossrankings.org/research/bcbs-fep-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z BCBS Federal Employee Program (FEP) GLP-1 Coverage: Standard Option, Basic Option, and FEP Blue Focus PA Pathway (2026) https://www.weightlossrankings.org/research/compounded-tirzepatide-vs-compounded-semaglutide Weight Loss Rankings en 2026-05-10T00:00:00.000Z Compounded Tirzepatide vs Compounded Semaglutide: Differences, Efficacy, Storage & Stability https://www.weightlossrankings.org/research/when-to-increase-mounjaro-dose-for-weight-loss Weight Loss Rankings en 2026-05-10T00:00:00.000Z When to Increase Your Mounjaro Dose for Weight Loss (Titration Decision Guide) https://www.weightlossrankings.org/research/minnesota-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Minnesota Medicaid (Medical Assistance / MHCP) GLP-1 Coverage (2026): Pattern #20 — Affirmative Obesity-Indication Coverage With Dedicated "Weight Management Agents" PDL Class (Saxenda/Wegovy Preferred; Zepbound Non-Preferred) + Active Hostile Exclusion Legislation (HF4142 Laid Over 3/25/2026) + FFS-Direct No-PBM Architecture + Tirzepatide in Two PDL Classes https://www.weightlossrankings.org/research/wisconsin-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Wisconsin Medicaid (ForwardHealth / BadgerCare Plus) GLP-1 Coverage (2026): Pattern #19 — Positive Coverage With Broadest Published AOM PA Criteria + 2-Lifetime-Attempt Cap + BMI < 24 Renewal-Revocation + No PBM Intermediary + Dual-Eligibles Medicare Part D Gap Fill https://www.weightlossrankings.org/research/where-to-inject-tirzepatide Weight Loss Rankings en 2026-05-10T00:00:00.000Z Where to Inject Tirzepatide: Best Site for Weight Loss + Pain Reduction https://www.weightlossrankings.org/research/glp1-shot-beginner-guide Weight Loss Rankings en 2026-05-10T00:00:00.000Z GLP-1 Shot: What It Is, Which Brands, How It Works (Beginner Guide) https://www.weightlossrankings.org/research/virginia-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Virginia Medicaid (Cardinal Care) GLP-1 Coverage (2026): Pattern #18 — Conditional Coverage With Highest Published BMI Threshold in Series (BMI > 40 Floor + BMI > 37 + Comorbidity) + Two-Level Step Therapy (Phentermine-then-Saxenda-then-Wegovy/Zepbound) + Active 2026 BALANCE-Conditional Legislation (SB30 Item 291 #5s / HB30 Item 291 #9h) + Forced Single-PBM Consolidation by July 1, 2026 (HB 2610 / SB 875) + 12VAC30-50-520 Unamended Since 1999 + Removed-GLP1-Exclusion Legislative History YMYL Trap https://www.weightlossrankings.org/research/maryland-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Maryland Medicaid GLP-1 Coverage (2026): Pattern #17 — Regulatory-Exclusion + Dual-Indication Carve-Out (Wegovy ASCVD + MASH via HCPCS J3490 Medical-Benefit Pathway) + Active "Authorization" Legislation in Conference Committee (COMAR 10.09.03.05(A)(14) + PT 35-25 + MDH Pharmacy News & Views Nov 2025 + SB 0496/HB 0813 2026 RS) https://www.weightlossrankings.org/research/indiana-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Indiana Medicaid (IHCP) GLP-1 Coverage (2026): Pattern #16 — Regulatory-Exclusion Adult Non-Coverage With EPSDT-Only Pediatric Carve-In and Zepbound-Preferred-for-T2D-Only Anomaly (405 IAC 5-24-3(b)(1) + December 1, 2025 OptumRx SUPDL V1.0 + HB 1202 Fiscal Note Adult-Exclusion Verbatim + IHCP Bulletin BT2023148 EPSDT Carve-In) https://www.weightlossrankings.org/research/massachusetts-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Massachusetts Medicaid (MassHealth) GLP-1 Coverage (2026): Pattern #15 — Two-Phase Termination Policy-Reversal (Jan 2024–Jun 2026 Positive Coverage Then Jul 1 2026 Chronic-Weight-Management Termination + MACE/MASH/OSA Phase 2 Carve-Outs + Healey Coordinated Retrenchment + 130 CMR 406.413(B) Anticipated-Forthcoming Procedural Anomaly) https://www.weightlossrankings.org/research/arizona-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Arizona Medicaid (AHCCCS) GLP-1 Coverage (2026): Pattern #12 — Agency-Manual Explicit Exclusion (AHCCCS FFS Provider Billing Manual Chapter 12, Item #13 + Uniform Contractor PDL Exclusions + Dual-Vendor PBM Stack + SB 1711 Deferred Dec 2025 + SB 1621 Advisory Council First Report Dec 2027) https://www.weightlossrankings.org/research/tennessee-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Tennessee Medicaid (TennCare) GLP-1 Coverage (2026): Pattern #13 — Positive-Coverage Expansion From Prior Categorical-Exclusion Baseline (Sequence 10-34-25 + 2025 Public Chapter 530 + Aug 1, 2025 Emergency Rule) — Wegovy + Zepbound Preferred, 5-Indication PA Form, Broadest No-PA AOM Panel in Series, Uniform Statewide MCO Carve-Out https://www.weightlossrankings.org/research/washington-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Washington Medicaid (Apple Health) GLP-1 Coverage (2026): Pattern #14 — YMYL-Trap / Indication-Anchored Coverage (KFF Lists WA as Covering; HCA's Own Policies Say "Not Covered by Apple Health for Weight Loss" — WAC 182-530-2100(1)(b)(i) + 42 U.S.C. § 1396r-8(d)(2)(A) + MACE/MASH/OSA Carve-Outs Operative Since July 2024) https://www.weightlossrankings.org/research/new-jersey-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z New Jersey Medicaid GLP-1 Coverage (2026): Pattern #11 — Dual-Authority Explicit Exclusion (N.J.A.C. § 10:51-1.13 + 42 U.S.C. § 1396r-8(d)(2)(A) + DMAHS Nov 2025 Memo) + Unprecedented Fiscal Transparency ($37.5M Current / $208.3M Full Coverage / $37.7M Net State-Fund Increase) + SHBP Inverse Coverage Contradiction https://www.weightlossrankings.org/research/michigan-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Michigan Medicaid GLP-1 Coverage (2026): Pattern #10 — Partial Retainment With Morbid-Obesity Gate (BMI ≥ 40) + Bariatric-Surgery-Avoidance Prescriber Attestation + Appropriations-Statute Authority https://www.weightlossrankings.org/research/pennsylvania-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Pennsylvania Medicaid GLP-1 Coverage 2026: The Policy Reversal — 34 Months of Coverage Terminated January 1, 2026 (MAB2025112403 + 55 Pa.B. 8828 + 55 Pa. Code § 1121.54) https://www.weightlossrankings.org/research/north-carolina-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z North Carolina Medicaid GLP-1 Coverage (2026): The Double-Reversal State — Covered (Aug 2024) → Terminated (Oct 2025) → Reinstated (Dec 2025), Wegovy Preferred, Most-Permissive Pathway in the 9-State Series https://www.weightlossrankings.org/research/georgia-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Georgia Medicaid GLP-1 Coverage (2026): Dual-Level Operational Non-Coverage — Statewide PDL Omission + Peach State Health Plan Explicit 'Drugs Prescribed for Weight Loss' Exclusion https://www.weightlossrankings.org/research/illinois-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Illinois Medicaid GLP-1 Coverage (2026): The Strictest Exclusion in the Series — Doubly-Anchored on 89 IAC § 140.441(b) + HFS PDL Absence, No Wegovy Carve-Back-In https://www.weightlossrankings.org/research/ohio-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Ohio Medicaid GLP-1 Coverage (2026): Triple-Anchored Weight-Loss Exclusion + the January 2026 Wegovy MACE/MASH Carve-Back-In https://www.weightlossrankings.org/research/weight-loss-injections-guide Weight Loss Rankings en 2026-05-10T00:00:00.000Z Weight Loss Injections Guide 2026 — Every FDA-Approved Option, Effectiveness, Cost, Safety https://www.weightlossrankings.org/research/florida-medicaid-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z Florida Medicaid GLP-1 Coverage (2026): The Silent Exclusion — What the AHCA PDL Says (and Doesn't Say) About Wegovy, Zepbound, and Weight Loss https://www.weightlossrankings.org/research/new-york-medicaid-nyrx-glp1-coverage-pa-pathway Weight Loss Rankings en 2026-05-10T00:00:00.000Z New York Medicaid (NYRx) GLP-1 Coverage (2026): Triple-Anchored Weight-Loss Exclusion + the Wegovy MACE Pathway https://www.weightlossrankings.org/research/glp1-depression-suicidality-evidence Weight Loss Rankings en 2026-05-10T00:00:00.000Z Does Tirzepatide / Semaglutide Cause Depression? FDA Postmarket Surveillance + Evidence Review https://www.weightlossrankings.org/research/glp1-ssri-antidepressant-interaction-weight-evidence Weight Loss Rankings en 2026-05-10T00:00:00.000Z SSRI + GLP-1: Drug Interactions, Weight Effects, and Combined Use Evidence https://www.weightlossrankings.org/research/glp1-diarrhea-weight-loss-mechanism-real-vs-fluid Weight Loss Rankings en 2026-05-10T00:00:00.000Z Does Diarrhea Cause Weight Loss on GLP-1s? Calorie-Loss vs Real Fat Loss Distinction https://www.weightlossrankings.org/research/glp1-ashwagandha-cortisol-stress-eating-evidence Weight Loss Rankings en 2026-05-10T00:00:00.000Z Ashwagandha and GLP-1: Cortisol, Stress Eating, and Combined Use Evidence https://www.weightlossrankings.org/research/glp1-stopping-rebound-weight-gain-evidence Weight Loss Rankings en 2026-05-10T00:00:00.000Z Stopping Wegovy / Zepbound / Ozempic: Rebound Weight Gain Evidence and Transition Planning